- Associated Press - Friday, June 15, 2018

NEW YORK (AP) - The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.

Week of June 18:

AVROBIO - Cambridge, Mass., 4.4 million shares, priced $16-$18, managed by Morgan Stanley/Cowen & Company. Proposed Nasdaq symbol AVRO. Business: Developing stem cell gene therapies to cure rare diseases.

Aptinyx - Evanston, Ill., 5.3 million shares, priced $14-$16, managed by JP. Morgan/Cowen & Company. Proposed Nasdaq symbol APTX. Business: Developing novel small molecule tharapeutics for neurological disorders.

Autolus Therapeutics - United Kingdom, 7.8 million shares, priced $15-$17, managed by Goldman Sachs/Jefferies. Proposed Nasdaq symbol AUTL. Business: Developing cancer therapies based on CAR-T cell technology.

Eidos Therapeutics - San Francisco, Calif., 6.3 million shares, priced $15-$17, managed by JP. Morgan/BofA Merrill Lynch. Proposed Nasdaq EIDX. Business: Developing a novel oral therapy for rare neurodegenerative diseases.

electroCore - Basking Ridge, N.J., 4.3 million shares, priced $14-$16, managed by Evercore ISI/Cantor Fitzgerald. Proposed Nasdaq symbol ECOR. Business: Commercializing a handheld nerve stimulation device for treating migraines.

Essential Properties Realty Trust - Princeton, N.J., 32.5 million shares, priced $14-$17, managed by Goldman Sachs/Citi. Proposed NYSE symbol EPRT. Business: Triple net lease REIT that manages single-tenant commercial properties.

i3 Verticals - Nashville, Tenn., 6.7 million shares, priced $11-$13, managed by Cowen & Company/Raymond James. Proposed Nasdaq symbol IIIV. Business: Provides integrated payment processing and software to SMBs.

Kezar Life Sciences - San Francisco, 4.7 million shares, priced $14-$16, managed by Jefferies/Cowen & Company. Proposed Nasdaq symbol KZR. Business: Developing proteasome inhibitors to treat autoimmune diseases.

LF Capital Acquisition - New York, 15.5 million shares, priced at $10, managed by B. Riley FBR/Raymond James. Proposed Nasdaq LFACU. Business: Blank check company targeting a business in the commercial banking or fintech industry.

Magenta Therapeutics - Cambridge, Mass., 6.7 million shares, priced $14-$16, managed by JP. Morgan/Goldman Sachs. Business: Developing novel therapies to make stem cell transplants more effective.

Xeris Pharmaceuticals - Chicago, 5 million shares, priced $14-$16, managed by Jefferies/Leerink Partners. Proposed Nasdaq symbol XERS. Business: Developing a novel formulation of an injectable hypoglycemia treatment.

Sign up for Daily Newsletters

Manage Newsletters

Copyright © 2019 The Washington Times, LLC.

Please read our comment policy before commenting.


Click to Read More and View Comments

Click to Hide